• The transaction replaces the existing alternative financing, establishes a progressive amortisation schedule and eliminates instruments with potential dilutive effect.
• The combination of the syndicated loan and the capital increase improves the company’s credit profile and expands its optionality for organic and inorganic growth, ultimately enhancing value creation for shareholders.

Madrid, 19 February 2026 – Labiana Health, the pharmaceutical laboratory specialised in animal and human health and listed on BME Growth, has formalised a syndicated financing facility for a total amount of €37 million, led by Deutsche Bank España as agent bank, together with Institut Català de Finances (ICF), Andorra Banc Agrícol Reig, CaixaBank and Banco Santander.

This refinancing and simplification of existing debt represents a strategic milestone for Labiana in the execution of its business plan, as it not only improves the company’s credit profile, but also expands its capacity for organic and inorganic growth and, ultimately, value creation for shareholders. The cancellation and replacement of the financing subscribed with Miralta Bank, S.A. and Blantyre Capital Limited alone benefits the company and its shareholders through lower financial costs and a progressive amortisation profile with more extended and structured maturities that prioritise cash generation, while also eliminating the dilution risk previously faced by shareholders.

Furthermore, the increased financing volume allows part of the funds to be allocated to CapEx financing, thereby aligning the financial structure with the medium- and long-term growth opportunities defined in the company’s business plan. It is also worth highlighting that the transaction includes a working capital facility, providing the company with greater operational flexibility.

A capital increase with pre-emptive subscription rights

Within the framework of this transaction and as a condition precedent to its effectiveness, Labiana will also carry out a capital increase with pre-emptive subscription rights for a maximum amount of €5.072 million, through the issuance of up to 1,268,000 new ordinary shares at a price of €4 per share.

The capital increase fully respects shareholders’ pre-emptive subscription rights, allowing them to maintain their proportional stake in the share capital. The subscription period will last 14 calendar days from the publication of the announcement in the Official Gazette of the Commercial Registry (BORME).

According to Manuel Ramos, CEO of Labiana, “the formalisation of this syndicated financing enables us to fully replace the previous structure with a long-term syndicated banking framework aligned with our industrial plan and featuring an orderly maturity schedule. The capital increase linked to this transaction has sufficient subscription commitments to cover the minimum required amount and is structured in full respect of pre-emptive subscription rights, with the aim of allowing all our shareholders to maintain their proportional participation in the company. We believe this structure is consistent with our commitment to the market and with the fair treatment of all our shareholders.”

Labiana considers that this transaction consolidates a solid and flexible financial structure aligned with the company’s sustainable growth, strengthening long-term value creation for all shareholders.

In the first half of 2025, Labiana recorded revenues of more than €39 million, with diversified activity in animal and human health and an international presence in over 150 markets.

All the terms and conditions of the syndicated financing and the capital increase are set out in the corresponding communications submitted to the market.